Parexel and JFCR Ink Pact To Advance Access To Oncology Clinical Trials

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, has announced a strategic alliance to accelerate access to oncology clinical trials in Japan.

Under the agreement, JFCR will join Parexel’s Global Site Alliance network, making it a preferred site for oncology clinical trials and providing more opportunities for Japanese patients to participate in cancer research. Parexel will leverage JFCR's expertise to help sponsors develop protocols that better align with Japan's standard of care and regulatory approval processes — resulting in streamlined patient recruitment and study start-up.

“Consistent with global trends, the incidence of cancer is expected to increase in Japan. We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase the access of potentially life-changing treatments to Japanese patients,” said Shigehiro Miki, Corporate Vice President and General Manager, Parexel, Japan.

“With experience spanning more than 115 years, JFCR is Japan’s first and largest medical organization dedicated to cancer care. The organization is known for its cross-functional, holistic cancer centre, state-of-the-art research facilities and extensive number of patients under their care. 

“Parexel and JFCR enter into this strategic alliance driven by a shared sense of urgency to enable sponsors to conduct trials in Japan and ensure these patients have access to innovative clinical research. To improve well-being of people worldwide by conquering cancer is the fundamental principle of JFCR. We look forward to collaborating closely with Parexel to realize our principle,”  said Dr Takeshi Sano, Hospital Director, Cancer Institute Hospital of JFCR.